Thompson Davis & Co., Inc. Savara Inc Transaction History

Thompson Davis & Co., Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 13, 2022	SELL	$1.05 - $1.36 $26,250 - $34,000	-25,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $26,000 - $33,500	25,000 New	25,000 $31,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Thompson Davis & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on Thompson Davis & Co., Inc. with notifications on news.